Menu
Recruiting NCT04185272

Butyrophilins Role in Colon Cancer

No phase Interventional Colonic Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: analysis of BTN and BTNL status.
Who it may be relevant to
Registry conditions: Colonic Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation

Overview

quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer

Interventions

  • Biological analysis of BTN and BTNL status
    analysis of BTN and BTNL expression in colon cancer and hepatic metastasis

Primary outcome measures

  • evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry [Time frame: 8 years]

Eligibility criteria

Inclusion criteria

  • Patient is older than 18 years old,
  • Signed participation consent,
  • Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.
  • Performance Status (PS) 0 or 1
  • affiliated to the social security or beneficiary

Exclusion criteria

  • Rectal cancer, colon cancer recurrence
  • Emergency of colon cancer Surgery
  • History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
  • Patient who received neoadjuvant therapy other than chemotherapy
  • Patient treated with immune-suppressors or long-course corticosteroids <12 months
  • Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding,
  • Person in urgent situation, person under legal protection measure, or unable to express his / her consent,
  • Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Basic science

Study locations

France · 1 center
  • Institut Paoli-Calmettes — Marseille

Identifiers

NCT: NCT04185272 · IMMUNOCOL-IPC 2019-018

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗